| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 16,250 | 16,270 | 13:29 | |
| 16,250 | 16,275 | 13:29 |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Gilead reaches $202M settlement over HIV drug speaker program | ||
| Di | Bernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock | ||
| Di | Fighting Disease Requires More Than Just the Right Drug: Gilead | ||
| Di | Gilead's twice-yearly HIV PrEP set for wider rollout | ||
| Mo | Merck wades deeper into HIV PrEP waters dominated by Gilead with 2 new late-stage trials |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | GSK telegraphs 'very limited number' of job cuts amid R&D investment spree | ||
| Di | GSK expands Medicines Patent Pool deal to allow generic production of cabotegravir for HIV treatment | ||
| Di | GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults | ||
| Di | JPMORGAN stuft GSK auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK auf "Underweight" mit einem Kursziel von 1425 Pence belassen. James D Gordon bezog sich in einer am Dienstag vorliegenden... ► Artikel lesen | |
| Di | As GSK eyes Blenrep's US return, FDA flags eye safety concerns ahead of advisory committee meeting |
| Unternehmen / Aktien | Kurs | % |
|---|---|---|
| GILEAD SCIENCES INC | 93,31 | -0,71 % |
| GSK PLC | 16,270 | +0,18 % |
